Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 1400 participants.

Also called NCT01500590

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,400 participants (enrolled count) (from the registry)
Sponsor
Hospital Authority, Hong Kong (from the registry)
Registry
  • NCT NCT01500590
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01500590. Randomized; no masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2018-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria
Acronym
eGFR
Condition
Diabetes
Condition
Hypertensive Disease
Intervention (Drug)
Renin-angiotensin system blockers
Intervention (Drug)
non-renin angiotensin system blockers
Lead sponsor
Hospital Authority, Hong Kong (class: other government)

Record details

Record id
cardio:ct-nct01500590
Content hash
5b2d815a41286f5cd47b6fd8e1d4792454613333073992e56b0b764ebc6466c5